Sign In
Buy MBRX
$0.400
-0.620 (-60.78%)
At Close: Jul 31, 2026
Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
09:15am, Thursday, 05'th Feb 2026
– Live video webcast on Wednesday, February 11 th at 1:20 PM EST
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects
08:55am, Tuesday, 13'th Jan 2026
– Annamycin consistently demonstrates no evidence of cardiotoxicity across five clinical trials – This next-generation anthracycline demonstrates safety and promising early activity in treating mu
– First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries – Investigator-Initiated (IIT) funded pancreatic and brain cancer trials HOUSTON, Jan. 12, 2026 (GLOBE NEWS
Emory University physician-sponsored clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children's Healthcare of Atlanta Results demonstrated WP1066 induces anti-tumor immune r
Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds
08:30am, Wednesday, 10'th Dec 2025
HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026
08:07am, Tuesday, 09'th Dec 2025
Continues to drive enrollment with increase to 78% now consented Blinded response activity tracking within expected range
Moleculin Announces New Annamycin Collaboration in Brain Tumors
08:21am, Monday, 08'th Dec 2025
Investigator-Initiated Preclinical studies at CIC biomaGUNE aimed at combatting Glioblastoma Multiforme Research will evaluate effects of intra-arterial delivery of Annamycin HOUSTON, Dec. 08, 2025
Moleculin to Participate in the Virtual Investor Closing Bell Series
09:15am, Wednesday, 26'th Nov 2025
Live video webcast with Walter Klemp, Chairman and Chief Executive Officer, on Tuesday, December 2 nd at 4:00 PM ET
Moleculin Announces Reverse Stock Split
09:00am, Wednesday, 26'th Nov 2025
HOUSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it filed an amendment to its amended and restated certif
Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented
08:36am, Thursday, 13'th Nov 2025
Completion of treatment for the first 45 patients on pace for Q1 2026 with initial unblinded data thereafter; blinded response activity tracking within expected range
Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill
08:37am, Wednesday, 12'th Nov 2025
Preclinical research to be conducted at the University of North Carolina at Chapel Hill (UNC) Annamycin will be used in conjunction with novel agents and modalities Preclinical studies indicate Anna
Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting
08:40am, Thursday, 30'th Oct 2025
HOUSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates
Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin
08:35am, Wednesday, 29'th Oct 2025
HOUSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates
Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer
08:00am, Thursday, 23'rd Oct 2025
Atlantic Health, a leading provider of health care based in New Jersey, to conduct the investigator-initiated Phase 1B/2 study Preclinical studies indicate Annamycin targets key factors in pancreatic
Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin
08:35am, Thursday, 25'th Sep 2025
HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidate
